Latest News
Web Date: November 13, 2017

Novartis taps Homology Medicines for viral-based gene editing

The duo aims to edit genetic blood and eye diseases using adeno-associated viruses (AAVs) rather than CRISPR
Department: Government & Policy

Novartis announced today that it is collaborating with Bedford, Mass.-based start-up Homology Medicines to expand its programs in gene therapy and gene editing to develop therapies for genetic blood and eye diseases.

Homology Medicines is in the business of developing adeno-associated viruses (AAVs), the mainstay delivery vehicle for gene therapy. The idea of delivering a healthy piece of DNA to compensate for a genetic disease is hardly new. Homology contends that varieties of AAV recently . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society